Aethlon Medical (NASDAQ:AEMD) Stock Passes Below 200 Day Moving Average – Here’s Why

Aethlon Medical, Inc. (NASDAQ:AEMD)’s stock price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $9.40 and traded as low as $2.66. Aethlon Medical shares last traded at $2.66, with a volume of 46,450 shares trading hands.

Analyst Ratings Changes

Several analysts have recently issued reports on AEMD shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aethlon Medical in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Aethlon Medical to a “sell” rating in a report on Saturday, August 30th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Reduce” and an average price target of $560.00.

Aethlon Medical Stock Down 3.6%

The firm has a 50 day moving average of $4.21 and a 200 day moving average of $9.35. The firm has a market cap of $1.95 million, a PE ratio of -0.11 and a beta of 1.64.

Aethlon Medical (NASDAQ:AEMD) last released its earnings results on Wednesday, November 12th. The medical equipment provider reported ($3.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.70) by ($2.04). On average, research analysts anticipate that Aethlon Medical, Inc. will post -0.73 EPS for the current year.

Institutional Investors Weigh In On Aethlon Medical

A hedge fund recently bought a new stake in Aethlon Medical stock. Armistice Capital LLC bought a new position in shares of Aethlon Medical, Inc. (NASDAQ:AEMD) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 1,427,946 shares of the medical equipment provider’s stock, valued at approximately $511,000. Armistice Capital LLC owned 8.89% of Aethlon Medical as of its most recent SEC filing. Institutional investors and hedge funds own 1.99% of the company’s stock.

About Aethlon Medical

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.